Abstract
INTRODUCTION: In the present study we aim to determine the effects of different inhibitors of the late sodium current (I(Na,late)) on vascular responses to adrenergic stimuli, both endogenous and exogenous. METHODS: The study was performed using specific inhibitors of I(Na,late) as GS-967, GS-6615 and Ranolazine (RAN). Rings from rabbit aorta were placed in organ baths chambers. RESULTS: Electrical Field Stimulation (EFS) (2, 4 and 8 Hz) induced frequency-dependent contractions that were abolished by tetrodotoxin, prazosin, or guanethidine (10(-6) M). The intervention of I(Na,late) was observed by incubating the aortic segments with GS-967, GS-6615 or RAN. Concentration-response curves to GS-967, GS-6615 or RAN were constructed in rings precontracted with noradrenaline, endothelin-1 or KCl with or without specific inhibitors (L-NAME, nimesulide, SC-560, verapamil, nifedipine, apamin or charybdotoxin). Contraction to noradrenaline were elicited in the absence or presence of I(Na,late) inhibitors (GS-967, GS-6615 or RAN). EFS induced frequency-dependent contractions of rings, mediated by noradrenaline acting on α(1)-adrenoceptors. I(Na,late) blockers GS-967 and GS-6615 reduced vasoconstriction induced by sympathetic nerve stimulation, effect reversed by charybdotoxin, implicating large-conductance Ca(2+)-activated K(+) channels. RAN elicited an attenuation of nerve-induced vasoconstriction, with 20% of this effect mediated via large-conductance Ca(2+)-activated K(+) channels. The predominant mechanism involved competitive antagonism of RAN at α(1)-adrenergic receptors. DISCUSSION: These findings suggest distinct mechanisms of action among I(Na,late) blockers, highlighting the involvement of large-conductance Ca(2+)-activated K(+) channels in GS-967 and GS-6615 effects, and a competitive α(1)-adrenoceptor antagonism for RAN. Taken together, our results indicate that GS-967, GS-6615 and RAN decrease vasoconstrictor responses due to both neural and noradrenaline-induced adrenergic stimuli. We can suggest that the use of GS-967, GS-6615 and Ranolazine may be interesting in clinical procedures involving hyperstimulation of the adrenergic nervous system.